Viyash Scientific Limited — Investor Meet, 16-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Viyash Scientific Limited hosted an earnings conference call to discuss the financial results for the first quarter of FY'27.

The company reported a strong quarter with revenue from operations at Rs. 946 Cr, up 20% YoY. EBITDA surged 59% YoY to Rs. 205 Cr, with margins expanding to 21.6%. Profit after tax more than doubled YoY to Rs. 79 Cr. Net debt reduced significantly to Rs. 86 Cr, resulting in a net debt to EBITDA of 0.1x. Animal Health Formulation business saw robust growth, and the US Human Formulation business grew 60% due to a shift towards complex, backward-integrated products. API revenue was flat sequentially due to raw material price volatility but is expected to rebound strongly. The company is set to acquire Bio For Life in Italy, strengthening its companion animal health focus. Management is optimistic about consistent performance, driven by new product launches, geographic expansion, and R&D investments, all while maintaining financial discipline. The overall sentiment is confident.